Substances tested
What has been given to the adipocyte, and what the adipocyte did. Research reference, not medical advice.
All substances 19
Insulin peptide hormone
acts on insulin receptor, then Akt and phosphodiesterase 3B (PDE3B)
Anti-lipolytic. Insulin activates PDE3B in adipocytes through Akt, lowering cAMP and shutting down the PKA-driven lipolytic cascade. Insulin-induced phosphorylation and activation of PDE3B in 3T3-L1 adipocytes was blocked by dominant-negative Akt; the S273A mutant was neither phosphorylated by insulin nor activated in adipocytes, placing Ser273 as the Akt site.
Insulin peptide hormone
acts on insulin receptor, then GLUT4 glucose transporter
Stimulates glucose transport by translocating transporters from an intracellular pool to the plasma membrane rather than by activating transporters already at the surface. The founding observation for insulin-regulated GLUT4 trafficking in the fat cell.
Mirabegron selective beta-3 adrenergic agonist
acts on ADRB3 (beta-3 adrenergic receptor)
Activates human brown adipose tissue. A single oral dose raised BAT metabolic activity on 18F-FDG PET/CT in all twelve subjects (p = 0.001) and increased resting metabolic rate by 203 plus or minus 40 kcal per day, a 13 percent rise (p = 0.001). BAT activity significantly predicted the change in resting metabolic rate.
Rosiglitazone (BRL49653) thiazolidinedione, antidiabetic
acts on PPARgamma (nuclear receptor)
Thiazolidinediones are potent and selective activators of PPARgamma. BRL49653 binds PPARgamma with a dissociation constant near 40 nM. Treating pluripotent C3H10T1/2 stem cells with BRL49653 drove efficient differentiation into adipocytes, linking the antidiabetic drug class directly to the adipogenic master regulator.
PPARgamma2 (forced expression, not a drug) transcription factor, reference point for the TZD target
acts on PPARgamma2
Forced expression of PPARgamma2 in fibroblasts is sufficient to convert them into adipocytes. Establishes PPARgamma as the master transcriptional regulator of adipogenesis and explains why a PPARgamma ligand is an adipogenic drug.
Nicotinic acid (niacin) B vitamin used as a lipid-lowering agent
acts on GPR109A (PUMA-G in mouse, HM74 in human), Gi-coupled
Anti-lipolytic. The orphan receptor PUMA-G/HM74 is highly expressed in adipose tissue and is a nicotinic acid receptor; binding lowers cAMP through Gi. In PUMA-G null mice the nicotinic acid induced fall in plasma free fatty acids and triglyceride was abolished, showing the receptor mediates the anti-lipolytic effect in vivo.
Atglistatin small-molecule enzyme inhibitor, preclinical
acts on ATGL (adipose triglyceride lipase, PNPLA2)
Blocks the rate-limiting first step of lipolysis. Atglistatin is selective for ATGL and reduces fatty acid mobilization in vitro and in vivo. The proof that the rate-limiting lipase is druggable.
ATGL (enzyme identification, not a drug) lipase, the target of atglistatin
acts on triacylglycerol in the lipid droplet
ATGL performs the rate-limiting hydrolysis of triacylglycerol to diacylglycerol plus a fatty acid. ATGL deletion causes massive lipid accumulation in adipose and cardiac tissue, confirming it as the dominant route by which the fat cell releases its stored lipid.
Atrial and brain natriuretic peptide (ANP, BNP) cardiac peptide hormones
acts on NPR-A natriuretic peptide receptor, cGMP and PKG
A lipolytic pathway in human fat that does not use cAMP. In isolated human fat cells ANP and BNP stimulated lipolysis as strongly as isoproterenol, with potency ANP greater than BNP greater than CNP; microdialysis confirmed the effect in abdominal subcutaneous adipose tissue. Blocking or activating PDE3B and inhibiting adenylyl cyclase altered the isoproterenol response but not the ANP response, establishing a cGMP-dependent and cAMP-independent route.
Cortisol and dexamethasone glucocorticoids
acts on glucocorticoid receptor
Pro-adipogenic on human preadipocytes. In serum-free chemically defined medium, cortisol produced potent dose-dependent stimulation of adipose differentiation of human subcutaneous stromal-vascular cells and could be replaced by dexamethasone, partly by aldosterone, but not by sex steroids. Differentiation extent fell markedly with donor age, up to 70 percent from young adults versus 5 to 10 percent from the oldest.
CL-316,243 selective beta-3 adrenergic agonist, research compound
acts on ADRB3
Thermogenic. Chronic treatment of young rats on a high-fat diet raised body temperature and 24 hour energy expenditure mainly through resting metabolic rate, with food intake unchanged and carcass fat reduced. Interscapular brown adipose tissue was markedly hypertrophied with three to fourfold increases in uncoupling protein and cytochrome oxidase content; mitochondria were smaller with unchanged UCP per mitochondrion.
FGF21 endocrine fibroblast growth factor
acts on FGF receptor with beta-Klotho, then PGC-1alpha
Drives browning of white adipose tissue. FGF21-deficient mice adapt poorly to chronic cold with diminished browning of white fat. Adipose-derived FGF21 acts in an autocrine and paracrine manner to raise UCP1 and other thermogenic genes, at least partly by increasing adipose PGC-1alpha protein independently of its mRNA.
Isoproterenol (isoprenaline) non-selective beta-adrenergic agonist
acts on beta-1 and beta-2 adrenergic receptors in human subcutaneous adipocytes
The reference lipolytic stimulus in human fat, and the paper that qualifies the beta-3 story in humans. Beta-3 mRNA is 20 percent of total beta-adrenoceptor transcripts in human subcutaneous adipocytes, but only CGP12177 among beta-3 agonists produced lipolysis, with 4 to 5 fold lower efficacy than isoprenaline. Nadolol, a beta-1 and beta-2 antagonist, blocked isoprenaline-stimulated lipolysis, showing isoprenaline acts solely through beta-1 and beta-2 in these cells and that human beta-3 contributes little.
Liraglutide GLP-1 receptor agonist
acts on GLP-1 receptor, acting through hypothalamic AMPK rather than directly on the adipocyte
Stimulates brown adipose thermogenesis and browning, but centrally. Central injection of liraglutide in mice stimulated BAT thermogenesis and adipocyte browning independent of nutrient intake; the mechanism maps to the hypothalamic ventromedial nucleus, and AMPK activation there was sufficient to blunt both effects. In a one year study of obese type 2 diabetic patients, exenatide and liraglutide both increased energy expenditure. The adipose effect in this paper is centrally mediated, not a direct adipocyte action.
AdipoRon small-molecule adiponectin receptor agonist, preclinical
acts on AdipoR1 and AdipoR2
Reproduces adiponectin signalling with an oral small molecule. AdipoRon bound both AdipoR1 and AdipoR2 in vitro and activated AMPK and PPAR-alpha, ameliorating insulin resistance and glucose intolerance in high-fat-fed mice; the effects were completely abolished in AdipoR1 and AdipoR2 double-knockout mice. It also ameliorated diabetes in db/db mice and prolonged their shortened lifespan on a high-fat diet. The abstract reports the tissue effects in muscle and liver; adiponectin itself is the adipocyte-derived ligand.
Irisin exercise-induced myokine
acts on white adipocytes, driving a brown-fat-like program
Browning agent released by muscle. Muscle PGC1-alpha increases FNDC5, which is cleaved and secreted as irisin; irisin acts on white adipose cells in culture and in vivo to stimulate UCP1 and a broad brown-fat-like gene program. Irisin is induced by exercise in mice and humans, and mildly raised blood irisin increased energy expenditure in mice without changes in movement or food intake, improving obesity and glucose homeostasis.
Metformin biguanide antidiabetic
acts on ERK1/2 and perilipin in the adipocyte (this abstract does not demonstrate AMPK)
Restrains lipolysis. Metformin attenuated TNF-alpha mediated lipolysis by suppressing ERK1/2 phosphorylation and reversing perilipin downregulation, and also restricted the acute lipolytic response to isoproterenol. High glucose raised basal glycerol release and enhanced both TNF-alpha and isoproterenol stimulated lipolysis; metformin suppressed basal and high-glucose-enhanced lipolysis. The commonly cited metformin to AMPK link is not supported by this abstract.
TNF-alpha pro-inflammatory cytokine, adverse pharmacology and a drug target
acts on TNFR1
Causes insulin resistance from within the fat cell. Adipose tissue expresses TNF-alpha, expression is elevated in obesity, and neutralising it in obese rodents restores insulin-stimulated glucose uptake. Establishes adipose TNF-alpha as a causal driver of obesity-linked insulin resistance and the fat cell as an endocrine organ acting on whole-body metabolism.
Norepinephrine (via UCP1, the thermogenic endpoint) catecholamine, the physiological ADRB3 ligand
acts on ADRB3, then UCP1 in the brown adipocyte inner mitochondrial membrane
The endpoint of adrenergic stimulation in brown fat. UCP1 in brown adipose mitochondria dissipates the proton gradient as heat rather than driving ATP synthesis; this is the bioenergetic basis of adrenergically driven non-shivering thermogenesis and the reason a beta-3 agonist raises metabolic rate.
Every row rests on a PubMed abstract, and every PMID in this file was resolved through check-pubmed.py with a confirmed title match on 2026-09-12. A dose the abstract does not state is written as such, never guessed. Research reference, not medical advice.